| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Dept of Medicine I, Ruhr University Bochum, Marienhospital Herne, Bochum, 2 Dept of Medicine, Bethesda Krankenhaus, Wuppertal, and 3 Dept of Medicine IV, Charite, Campus Benjamin Franklin, Berlin, Germany
CORRESPONDENCE: B.M. Sanner, Dept of Medicine, Bethesda Krankenhaus, Hainstr. 35, 42109 Wuppertal, Germany. Fax: 49 2022902005. E-mail: Bernd.Sanner@ruhr-uni-bochum.de
Keywords: leptin, obesity, sleep, sympathetic nervous system
Received: July 28, 2002
Accepted November 18, 2003
Obstructive sleep apnoea syndrome (OSAS) is a common disorder in obesity. Leptin, an adipocyte-derived signalling factor, plays an important role in metabolic control. There is growing evidence that leptin regulation is altered in OSAS. Therefore, the aim of this study was to test the hypothesis that effective treatment will influence leptin levels in OSAS patients.
Serum leptin levels were determined in 86 consecutive patients (aged 57.5±11.0 yrs) with polysomnographically verified OSAS. In addition, leptin levels were reassessed and treatment efficacy was evaluated by polysomnography after 6 months of therapy.
Patients were treated with continuous or bilevel positive airway pressure, a mandibular advancement device or conservatively, depending on the clinical symptoms. Mean serum leptin levels did not change with treatment in the whole study group (7.3±5.0 versus 7.5±4.8 ng·mL–1), however, leptin levels decreased in effectively treated patients (8.5±5.0 versus 7.4±5.1 ng·mL–1) while they increased in ineffectively treated patients (5.0±4.0 versus 7.7±4.1 ng·mL–1). Furthermore, not only was there a significant and independent correlation between the change in leptin levels with treatment and the change in body mass index, but also with the change in apnoea/hypopnoea index.
Effective treatment of sleep-disordered breathing may have significant effects on leptin levels in obstructive sleep apnoea syndrome patients. Changes in leptin levels are related to changes in apnoea/hypopnoea index in obstructive sleep apnoea syndrome patients.
This article has been cited by other articles:
|
|
 |
|
  E. Tasali and M. S. M. Ip Obstructive Sleep Apnea and Metabolic Syndrome: Alterations in Glucose Metabolism and Inflammation Proceedings of the ATS, February 15, 2008; 5(2): 207 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Pillar and N. Shehadeh Abdominal Fat and Sleep Apnea: The chicken or the egg? Diabetes Care, February 1, 2008; 31(Supplement_2): S303 - S309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hanaoka, X. Yu, K. Urushihata, M. Ota, K. Fujimoto, and K. Kubo Leptin and Leptin Receptor Gene Polymorphisms in Obstructive Sleep Apnea Syndrome Chest, January 1, 2008; 133(1): 79 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Buyse and the participants of working group 2 Treatment effects of sleep apnoea: where are we now? Eur. Respir. Rev., December 1, 2007; 16(106): 146 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. T. McNicholas Cardiovascular outcomes of CPAP therapy in obstructive sleep apnea syndrome Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1666 - R1670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Campo, G. Fruhbeck, J. J. Zulueta, J. Iriarte, L. M. Seijo, A. B. Alcaide, J. B. Galdiz, and J. Salvador Hyperleptinaemia, respiratory drive and hypercapnic response in obese patients Eur. Respir. J., August 1, 2007; 30(2): 223 - 231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Chasens Obstructive Sleep Apnea, Daytime Sleepiness, and Type 2 Diabetes The Diabetes Educator, May 1, 2007; 33(3): 475 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. T. McNicholas, M. R. Bonsignore, and the Management Committee of EU COST ACTION B26 Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities Eur. Respir. J., January 1, 2007; 29(1): 156 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Spiegel, K. Knutson, R. Leproult, E. Tasali, and E. V. Cauter Sleep loss: a novel risk factor for insulin resistance and Type 2 diabetes J Appl Physiol, November 1, 2005; 99(5): 2008 - 2019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Barcelo, F. Barbe, E. Llompart, M. de la Pena, J. Duran-Cantolla, A. Ladaria, M. Bosch, L. Guerra, and A. G. N. Agusti Neuropeptide Y and Leptin in Patients with Obstructive Sleep Apnea Syndrome: Role of Obesity Am. J. Respir. Crit. Care Med., January 15, 2005; 171(2): 183 - 187. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
